# Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis

> **NCT06609343** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 16 (estimated)

## Conditions studied

- End Stage Renal Disease
- Fatigue

## Interventions

- **DRUG:** Bupropion Hydrochloride 150 MG

## Key facts

- **NCT ID:** NCT06609343
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2026-11-30
- **Final completion:** 2027-01-30
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06609343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06609343, "Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06609343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*